@article{be3b4fca585d43769a4eb7cbdf5a3b6f,
title = "Reply",
author = "Long, {Michelle T.} and Mazen Noureddin and Lim, {Joseph K.}",
note = "Funding Information: Conflicts of interest The authors disclose the following: Michelle T. Long is an employee of Novo Nordisk and receives research grant support from Echosens Corporation and Gilead Sciences. Mazen Noureddin has been on the advisory board/consultant for 89BIO, Altimmune, Gilead, cohBar, Cytodyn, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Madrgial, NorthSea, Prespecturm, Terns, Siemens, and Roche Diagnostic; has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis , Pfizer , Shire , Viking, and Zydus; and is a shareholder or has stocks in Anaetos, Chrownwell, Ciema, Rivus Pharma, and Viking. Joseph K. Lim has received research contracts (to Yale University) from Allergan, Celgene, Genfit, Gilead, Intercept, Pfizer, and Viking. Funding Information: Funding Michelle T. Long is supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK113252), the Boston University School of Medicine Department of Medicine Career Investment Award, the Doris Duke Foundation , and the Boston University Clinical Translational Science Institute (UL1 TR001430). ",
year = "2023",
month = mar,
doi = "10.1053/j.gastro.2022.10.037",
language = "English (US)",
volume = "164",
pages = "503",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",
}